Efavirenz (Sustiva™) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HrV-infected patients and has been in the market since 1998. Efavirenz exists as three different polymorphs (Forms I, II, III) and a nonstochiometric heptane solvate (Form IV). The current synthetic process for Efavirenz yields Form IV which is converted to the desired Form I polymorph by heating. One of the concerns for any drug substance is whether a consistent crystal form is produced in order to insure consistent physical and chemical properties, as well as to safeguard pharmacokinetic profiles. The sensitivity and resolution of single-crystal x-ray diffraction, the traditional method employed to determine unit cell parameters of drug compounds in development, are limited for Efavirenz Form IV because of the small crystallite size of the material. Furthermore, Efavirenz Form IV materials, depending on the process conditions, have slightly different powder diffraction patterns in terms of intensity when collected on standard in-house diffractometers.